EUVIMEDEUVIMED entdecken
Crossref

Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response

Sun Ok Jang, Jae Hyun Lee, Yong-Ju Chung, Hyun-Seok Oh, Myeongcheol Shin, Soo-Ok Kim, Sun Pyo Hong

Virology · 2024

DOI: 10.1016/j.virol.2024.110243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Virology, 2024. Verfasst von Sun Ok Jang und 6 weiteren Autor:innen. Beteiligte Einrichtung: R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea. Hauptthemen laut MEDLINE: Adenoviridae, Mice, Inbred C57BL, Viral Envelope Proteins, Herpes Zoster Vaccine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Ministry of Food and Drug Safety.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herpes zoster (HZ), or shingles, is caused by reactivation of the varicella-zoster virus (VZV), which remains latent in the sensory ganglia until immunity wanes with age. The representative HZ vaccine, Shingrix is efficacious but causes side effects due to vaccine adjuvants. Therefore, the development of highly efficacious vaccines with minimal side effects is required. We developed chimeric adenovirus vector (ChimAd)-based HZ vaccine candidates encoding the VZV glycoprotein E (gE). These candidates include ChimAd-tPAgE, in which the signal peptide is replaced with tissue plasminogen activator (tPA), and ChimAd-WTgE, which retains the original signal peptide. C57BL/6 mice were immunized with VZV-vaccine candidates, and cellular and humoral immune responses were evaluated using interferon-γ ELISPOT and ELISA. The ChimAd-based HZ vaccines induced high levels of gE-specific antibodies and cell-mediated immunity. ChimAd-tPAgE (optimal dose: 1 × 107 IFU) elicited a more robust gE-specific T-cell response than Shingrix and Zostavax, showing potential as HZ prophylactic vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoviridaeMice, Inbred C57BLViral Envelope ProteinsHerpes Zoster VaccineT-LymphocytesHerpesvirus 3, HumanAntibodies, ViralTissue Plasminogen ActivatorAnimalsMiceHerpes ZosterProtein Sorting SignalsFemaleHumansImmunity, CellularGenetic Vectors

Stichwörter der Autor:innen

Cell-mediated immunityChimeric adenovirus vectorGlycoprotein EVaricella-zoster virus

Substanzen

Viral Envelope ProteinsHerpes Zoster VaccineAntibodies, ViralTissue Plasminogen Activatorglycoprotein E, varicella-zoster virusProtein Sorting Signals

Autor:innen und Institutionen

  • R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea.
  • R&D Center, GeneMatrix, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea. Electronic address: sunphong@genematrix.net.

Förderung

  • Ministry of Food and Drug Safety

Zitieren

APA

Jang, S. O., Lee, J. H., Chung, Y. J., Oh, H. S., Shin, M., Kim, S. O., & Hong, S. P. (2024). Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response. Virology. https://doi.org/10.1016/j.virol.2024.110243

Vancouver

Jang SO, Lee JH, Chung YJ, Oh HS, Shin M, Kim SO, et al. Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response. Virology. 2024. doi:10.1016/j.virol.2024.110243

BibTeX
@article{Jang2024,
  author = {Jang, Sun Ok and Lee, Jae Hyun and Chung, Yong-Ju and Oh, Hyun-Seok and Shin, Myeongcheol and Kim, Soo-Ok and Hong, Sun Pyo},
  title = {Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response},
  journal = {Virology},
  year = {2024},
  doi = {10.1016/j.virol.2024.110243}
}
Kostenlos starten →